INOVIO Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. INOVIO is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices. It has no approved products and reported no product revenue.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $0 | $115,000 |
| Research and development expense | $20.9 million | $30.2 million |
| General and administrative expense | $10.6 million | $13.9 million |
| Operating loss | $31.5 million | $44.0 million |
| Net loss | $30.5 million | $40.6 million |
| Basic and diluted loss per share | $1.31 | $1.89 |
| Net cash used in operating activities | $28.8 million | $36.7 million |
| Cash, cash equivalents and short-term investments | $105.6 million | $145.3 million at December 31, 2023 |
| Working capital | $88.3 million | $110.5 million at December 31, 2023 |
| Total liabilities | $34.7 million | $53.6 million at December 31, 2023 |
Operating expenses were $31.5 million, down 29% year over year. Gross margin is not meaningful because the company reported no revenue. Cash and short-term investments declined by $39.7 million from year-end; the quarter’s $45.4 million investing cash inflow largely reflected investment sales and maturities, while financing cash outflow included repayment of the convertible notes.
Material changes and unusual items
- Research and development expense fell by $9.3 million, mainly from reduced COVID-19 program manufacturing and discontinued or scaled-back programs. Lower INO-3107 manufacturing costs partially offset these savings: INO-3107 R&D expense rose to $7.6 million from $3.3 million.
- General and administrative expense declined by $3.3 million, reflecting lower compensation and the absence of certain litigation expenses recorded in 2023.
- Grant contributions recorded as reductions to R&D expense fell to $179,000 from $3.1 million. Interest income also decreased to $1.5 million from $2.2 million, primarily due to a smaller investment balance.
- The company repaid its 6.50% convertible senior notes at maturity on March 1, 2024; the remaining obligation was approximately $16.9 million including accrued interest. No convertible notes remained on the March 31 balance sheet.
- INOVIO raised $5.2 million net through its ATM sales agreement during the quarter, issuing 543,620 shares. The associated registration statement expired as of March 31, so further sales under that agreement were unavailable as of the filing.
- A 1-for-12 reverse stock split took effect in January 2024; reported share and per-share figures have been retroactively adjusted.
Outlook, management commentary and risks
- Management expects cash and short-term investments, including proceeds from an April 18, 2024 registered direct offering, to fund planned operations for at least 12 months from the financial statements’ issuance. The MD&A estimates cash runway into the third quarter of 2025, excluding future financing. The company says current resources will not fund full clinical development beyond INO-3107 and expects to need additional capital.
- The April offering generated approximately $33.2 million net. It included 2,536,258 common shares and pre-funded warrants for up to 2,135,477 additional shares, creating potential dilution.
- INO-3107 is the lead candidate for recurrent respiratory papillomatosis. The company plans to submit a BLA under the FDA accelerated approval pathway in the second half of 2024 and says the FDA indicated the completed Phase 1/2 data could support a submission. The company also plans to initiate a confirmatory trial before BLA submission. Approval, timing and commercial success remain uncertain.
- Other development efforts include INO-3112 for HPV-related oropharyngeal cancer, in a planned collaboration with Coherus, and INO-5401 for glioblastoma. ApolloBio continues VGX-3100 development in China; INOVIO discontinued U.S. development for that indication in 2023. Advaccine continues INO-4800 development at its own expense.
- Key risks include ongoing losses and reliance on additional financing; clinical, regulatory and manufacturing uncertainty; dependence on collaborators, grants and contract manufacturers; competition; and exposure to litigation. The company disclosed pending VGXI supply-agreement litigation and GeneOne litigation; a hearing on INOVIO’s summary-judgment motion in the GeneOne matter was set for June 28, 2024. Outcomes and potential financial effects are not clearly quantified in the filing.
- The investment portfolio had $3.4 million of aggregate unrealized losses at March 31, primarily attributed to interest-rate movements; management reported no credit-loss allowance for available-for-sale debt securities. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether INOVIO files the INO-3107 BLA on its stated timetable and satisfies FDA filing and confirmatory-trial requirements.
- Actual cash use and financing needs against management’s stated runway, including the effect of future clinical spending and any additional equity issuance.
- The potential share dilution from the April offering warrants and the company’s subsequent share count.
- Clinical and regulatory progress for INO-3107 and other pipeline programs, including partner-led programs and grant funding.
- Developments and any financial exposure in the VGXI and GeneOne litigation.